Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 353 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: bupropion hydrochloride Clear all
Completed Phase 2 Interventional

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

NCT04634071
View directory record Official record
Conditions
Smoking Cessation, Cancer, Treatment-Related
Interventions
Varenicline, Bupropion, Long-acting nicotine replacement therapy, Low-intensity counseling, High-intensity counseling, No nicotine replacement therapy, Nicotine Replacement Products
Drug · Behavioral · Other
Lead sponsor
Joseph Valentino, MD
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Bowling Green, Kentucky • Lexington, Kentucky • Owensboro, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment

NCT02676375
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia
Interventions
Combination Bupropion + NRTs, Extended Treatment, Home Visits & Calls, Monotherapy
Drug · Other
Lead sponsor
Brentwood Biomedical Research Institute
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

NCT00320723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
bupropion, transdermal nicotine patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2009 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 2 Interventional

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

NCT00709371
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide SR placebo/ bupropion SR placebo, Zonisamide SR placebo/ bupropion SR 360 mg/day, Zonisamide SR 120 mg/day/ bupropion SR placebo, Zonisamide SR 360 mg/day/ bupropion SR placebo, Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day, Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fairhope, Alabama • La Jolla, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

NCT00567255
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Sep 30, 2026, 6:54 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Sep 30, 2026, 6:54 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

Research Evaluating the Value of Augmenting Medication With Psychotherapy

NCT00057551
View directory record Official record
Conditions
Depression, Depressive Disorder
Interventions
Brief Supportive Psychotherapy, CBASP, Medication Only
Behavioral · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Tucson, Arizona • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Mobile Contingency Management for Marijuana and Tobacco Cessation

NCT02869451
View directory record Official record
Conditions
Cigarette Smoking, Marijuana Abuse
Interventions
bupropion, transdermal nicotine patch, Nicotine polacrilex, nicotine lozenge, counseling for marijuana and smoking cessation, mobile contingency management
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

High Dose Bupropion for Smoking Cessation - Pilot Study

NCT03326128
View directory record Official record
Conditions
Smoking Cessation, Smoking, Tobacco, Smoking (Tobacco) Addiction, Cessation, Tobacco, Cigarette Smoking
Interventions
Bupropion Hydrochloride
Drug
Lead sponsor
University of Southern California
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 4 Interventional Results available

Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

NCT00449007
View directory record Official record
Conditions
Depression, Alcoholism, Suicidal Behavior
Interventions
fluoxetine, bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

NCT06736509
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Peoria, Arizona • Walnut Creek, California • Bonita Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 1 Interventional

Dopamine Reuptake Inhibitors of Cocaine Abuse - 1

NCT00000276
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 30, 2026, 6:54 AM EDT
Not yet recruiting Not applicable Interventional

Methamphetamine Use Disorder Support in Heart Failure Pilot Study

NCT07211724
View directory record Official record
Conditions
Heart Failure, Methamphetamine Use Disorder
Interventions
MUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bupropion on Seizure Threshold in Depressed Patients

NCT03126682
View directory record Official record
Conditions
MDD
Interventions
Wellbutrin SR 300Mg Extended-Release Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations

NCT01156610
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Tobacco Treatment
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combining Varenicline and Bupropion for Smoking Cessation

NCT00943618
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Bupropion, Placebo, Counseling/Phone Calls
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 70 Years
Enrollment
641 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

NCT01811147
View directory record Official record
Conditions
Bipolar Disorder, Major Depression
Interventions
Selective Serotonin Reuptake Inhibitor (SSRI)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
15 Years to 30 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Combinations of Pharmacologic Smoking Cessation Treatments

NCT00018187
View directory record Official record
Conditions
Smoking
Interventions
Bupropion, Mecamylamine, Nicotine Patch
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

NCT00865462
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combined Pharmaco/Behavior Therapy in Adolescent Smokers

NCT00330187
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Use Disorder
Interventions
Bupropion SR, Contingency Management, Placebo
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 30, 2026, 6:54 AM EDT
Withdrawn Phase 4 Interventional

Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

NCT03278938
View directory record Official record
Conditions
Depressive Illness
Interventions
bupropion, citalopram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 4 Interventional

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

NCT05537584
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sertraline, Bupropion
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Brain Reaction to Treatment of Nicotine Dependence

NCT00108173
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Zyban
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Sep 30, 2026, 6:54 AM EDT